HYPID (Pulmonary Hypertension in Interstitial Lung Disease) EXTENSION

Overview

HYPID-2 study is an extension of HYPID study (NCT01443598) :

HYPID-2 is also an observational and prospective study of patients with interstitial lung disease and pre capillary hypertension diagnosed by right heart sided catheterization.

It concerns only incident patients (i.e patients included within 6 months after PH diagnosis) whereas HYPID concerned prevalent and incident cases.

The primary aim is the same than HYPID : identify prognostic factors

Full Title of Study: “Observational Study of Incident Patients With Pre Capillary Pulmonary Hypertension and Interstitial Lung Disease”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 2018

Detailed Description

Pre capillary pulmonary hypertension (PH) may be present in patients with diffuse interstitial lung disease.

In this context, PH represents an important factor of morbidity and mortality for these patients.

As in HYPID, the main purpose of HYPID-2 is to determine predictive factors of mortality within this cohort of incident patients (i.e patients included within 6 months after PH diagnosis).

In order to reach that aim,the study includes an evaluation based on exams conducted for the routine follow-up of incident patients.

Each incident patient will be followed during 2 years at least.

Clinical Trial Outcome Measures

Primary Measures

  • Overall survival
    • Time Frame: 2 years
    • Determine predictive factors of mortality

Secondary Measures

  • Progression-free survival
    • Time Frame: 2 years
    • Time to death or 10% decline in FVC
  • Response to therapy
    • Time Frame: 2 years
    • Proposition of patients with 10% or more decline in PVR

Participating in This Clinical Trial

Inclusion Criteria

Patients newly diagnosed with:

  • Pre capillary pulmonary hypertension at right heart sided catheterization with: mPAP > or = 25 mmHg, PCWP < or = 15 mmHg
  • Interstitial lung disease with diffuse infiltrative opacities on chest CT scan

Exclusion Criteria

  • Pulmonary hypertension related to a thromboembolic disease
  • Respiratory disease other than diffuse interstitial lung disease
  • Any etiological factor of pulmonary arterial hypertension based on NICE 2013 classification other than diffuse interstitial lung disease
  • Any progressive disease associated to a life expectancy less than 6 months other than pulmonary hypertension, diffuse interstitial lung disease and respiratory insufficiency

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Groupe d’Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
  • Collaborator
    • Hospices Civils de Lyon
  • Provider of Information About this Clinical Study
    • Principal Investigator: Vincent COTTIN, Professor Vincent COTTIN – Groupe d’Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
  • Overall Official(s)
    • Vincent COTTIN, MD, Principal Investigator, Hospices civils de Lyon / Universit√© Lyon I

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.